<p>CRISPR Therapeutics AG（纳斯达克股票代码：CRSP - 获取免费报告）的股票在覆盖该公司的十八位分析师中获得了 “适度买入” 的平均评级，MarketBeat Ratings 报告称。两位研究分析师对该股票给予了卖出评级，五位给予了持有评级，十位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的经纪人对该股票的平均 12 个月目标价格为 66.0625 美元。</p>
<ul>
<li>3 只可能受益于专利悬崖的生物科技股票</li>
</ul>
<p>CRSP 最近成为几份研究报告的主题。TD Cowen 在 2 月 13 日的研究报告中将 CRISPR Therapeutics 的目标价格从 40.00 美元上调至 45.00 美元，并给予该股票 “持有” 评级。花旗集团在 5 月 6 日的研究报告中将 CRISPR Therapeutics 的目标价格从 80.00 美元上调至 82.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 3 月 17 日的研究报告中重申了 “增持” 评级，并将 CRISPR Therapeutics 的目标价格设定为 110.00 美元（上调自 105.00 美元）。华尔街 Zen 在周六的研究报告中将 CRISPR Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Needham &amp; Company LLC 在 2 月 13 日的研究报告中将 CRISPR Therapeutics 的目标价格从 80.00 美元上调至 82.00 美元，并给予该公司 “买入” 评级。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们对 CRSP 的最新分析</strong></p>
<h2>CRISPR Therapeutics 价格表现</h2>
<ul>
<li>CRISPR Therapeutics 在收益发布后上涨，管线希望增加</li>
</ul>
<p>CRSP 的股票在周二以 54.01 美元开盘。CRISPR Therapeutics 的 52 周低点为 34.87 美元，52 周高点为 78.48 美元。该公司的 50 日移动平均价格为 52.18 美元，200 日移动平均价格为 54.13 美元。公司的市值为 52.1 亿美元，市盈率为-8.68，贝塔值为 1.74。该公司的速动比率为 17.96，流动比率为 17.97，债务与股本比率为 0.32。</p>
<p>CRISPR Therapeutics（纳斯达克股票代码：CRSP - 获取免费报告）最后一次公布财报是在 3 月 31 日。该公司报告本季度每股收益为（1.28 美元）。CRISPR Therapeutics 的股本回报率为-25.66%，净利润率为-13,856.54%。该业务本季度的收入为 146 万美元。研究分析师平均预测 CRISPR Therapeutics 在当前财政年度的每股收益为-5.07 美元。</p>
<h2>CRISPR Therapeutics 的内部买卖</h2>
<ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
<p>在其他 CRISPR Therapeutics 的新闻中，首席执行官 Samarth Kulkarni 在 3 月 23 日的交易中出售了 10,020 股股票。股票以平均价格 46.78 美元出售，总价值为 468,735.60 美元。出售后，首席执行官直接持有该公司 255,501 股股票，价值约为 11,952,336.78 美元。这代表其持股减少了 3.77%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Naimish Patel 在 3 月 16 日的交易中出售了 3,150 股股票。股票以平均价格 48.26 美元出售，总交易额为 152,019.00 美元。出售完成后，内部人士直接持有该公司 13,143 股股票，价值约为 634,281.18 美元。这代表其持股减少了 19.33%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士已出售 51,828 股公司股票，价值为 2,578,097 美元。内部人士持有公司股票的 4.10%。</p>
<h2>机构投资者对 CRISPR Therapeutics 的看法</h2>
<p>一些大型投资者最近调整了对该公司的持股。Mcguire Capital Advisors Inc.在第四季度购买了 CRISPR Therapeutics 的新头寸，价值 25,000 美元。Ramirez Asset Management Inc.在第四季度购买了 CRISPR Therapeutics 的新头寸，价值 26,000 美元。Rothschild Investment LLC 在第四季度将其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 现在拥有 562 股该公司股票，价值 29,000 美元，此前在上个季度又购买了 502 股。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度将其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc.现在拥有 576 股该公司股票，价值 30,000 美元，此前在上个季度又购买了 382 股。最后，Optiver Holding B.V.在第三季度将其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V.现在拥有 504 股该公司股票，价值 33,000 美元，此前在上个季度又购买了 210 股。69.20% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 CRISPR Therapeutics</h2>
<p>（获取免费报告）</p>
<p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术修改人类细胞中的基因，旨在为一系列严重疾病创造持久的治疗方案。其研发工作集中在体外和体内应用，能够针对性地修正或破坏致病基因。</p>
<p>其主要项目之一是 CTX001，这是一种体外编辑的细胞疗法，旨在治疗镰状细胞病和依赖输血的β-地中海贫血，与 Vertex Pharmaceuticals 合作。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外向下，三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元于 CRISPR Therapeutics 吗？</h2>
<p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRISPR治疗

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>CRISPR Therapeutics AG（纳斯达克代码：CRSP）获得了来自十八位分析师的 “适度买入” 平均评级。该股票有两个卖出、五个持有、十个买入和一个强烈买入的推荐。平均 12 个月目标价为 66.06 美元。最近的目标价包括 TD Cowen 的持有评级为 45 美元、花旗集团的买入评级为 82 美元，以及派珀·桑德勒的增持评级为 110 美元。该股票开盘价为 54.01 美元，52 周区间为 34.87 美元至 78.48 美元。公司报告上个季度每股亏损 1.28 美元，收入为 146 万美元</p>

<p>Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the eighteen analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $66.0625.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG（纳斯达克股票代码：CRSP - 获取免费报告）的股票在覆盖该公司的十八位分析师中获得了 “适度买入” 的平均评级，MarketBeat Ratings 报告称。两位研究分析师对该股票给予了卖出评级，五位给予了持有评级，十位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的经纪人对该股票的平均 12 个月目标价格为 66.0625 美元。</p>
</div><ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能受益于专利悬崖的生物科技股票</li>
</ul>
</div><p>CRSP has been the topic of several recent research reports. TD Cowen upped their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a &#34;hold&#34; rating in a research note on Friday, February 13th. Citigroup increased their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, May 6th. Piper Sandler reissued an &#34;overweight&#34; rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen raised shares of CRISPR Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, Needham &amp; Company LLC increased their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, February 13th.</p>
<div class="lb-trans"><p>CRSP 最近成为几份研究报告的主题。TD Cowen 在 2 月 13 日的研究报告中将 CRISPR Therapeutics 的目标价格从 40.00 美元上调至 45.00 美元，并给予该股票 “持有” 评级。花旗集团在 5 月 6 日的研究报告中将 CRISPR Therapeutics 的目标价格从 80.00 美元上调至 82.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 3 月 17 日的研究报告中重申了 “增持” 评级，并将 CRISPR Therapeutics 的目标价格设定为 110.00 美元（上调自 105.00 美元）。华尔街 Zen 在周六的研究报告中将 CRISPR Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Needham &amp; Company LLC 在 2 月 13 日的研究报告中将 CRISPR Therapeutics 的目标价格从 80.00 美元上调至 82.00 美元，并给予该公司 “买入” 评级。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Analysis on CRSP</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CRSP 的最新分析</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 价格表现</h2>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在收益发布后上涨，管线希望增加</li>
</ul>
</div><p>Shares of CRSP opened at $54.01 on Tuesday. CRISPR Therapeutics has a fifty-two week low of $34.87 and a fifty-two week high of $78.48. The firm's 50 day moving average price is $52.18 and its 200 day moving average price is $54.13. The company has a market cap of $5.21 billion, a P/E ratio of -8.68 and a beta of 1.74. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32.</p>
<div class="lb-trans"><p>CRSP 的股票在周二以 54.01 美元开盘。CRISPR Therapeutics 的 52 周低点为 34.87 美元，52 周高点为 78.48 美元。该公司的 50 日移动平均价格为 52.18 美元，200 日移动平均价格为 54.13 美元。公司的市值为 52.1 亿美元，市盈率为-8.68，贝塔值为 1.74。该公司的速动比率为 17.96，流动比率为 17.97，债务与股本比率为 0.32。</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million for the quarter. On average, research analysts forecast that CRISPR Therapeutics will post -5.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（纳斯达克股票代码：CRSP - 获取免费报告）最后一次公布财报是在 3 月 31 日。该公司报告本季度每股收益为（1.28 美元）。CRISPR Therapeutics 的股本回报率为-25.66%，净利润率为-13,856.54%。该业务本季度的收入为 146 万美元。研究分析师平均预测 CRISPR Therapeutics 在当前财政年度的每股收益为-5.07 美元。</p>
</div><h2>Insider Buying and Selling at CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 的内部买卖</h2>
</div><ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
</div><p>In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 10,020 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares in the company, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 51,828 shares of company stock valued at $2,578,097. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 CRISPR Therapeutics 的新闻中，首席执行官 Samarth Kulkarni 在 3 月 23 日的交易中出售了 10,020 股股票。股票以平均价格 46.78 美元出售，总价值为 468,735.60 美元。出售后，首席执行官直接持有该公司 255,501 股股票，价值约为 11,952,336.78 美元。这代表其持股减少了 3.77%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Naimish Patel 在 3 月 16 日的交易中出售了 3,150 股股票。股票以平均价格 48.26 美元出售，总交易额为 152,019.00 美元。出售完成后，内部人士直接持有该公司 13,143 股股票，价值约为 634,281.18 美元。这代表其持股减少了 19.33%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士已出售 51,828 股公司股票，价值为 2,578,097 美元。内部人士持有公司股票的 4.10%。</p>
</div><h2>Institutional Investors Weigh In On CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 CRISPR Therapeutics 的看法</h2>
</div><p>A number of large investors have recently modified their holdings of the company. Mcguire Capital Advisors Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $26,000. Rothschild Investment LLC grew its position in shares of CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after buying an additional 502 shares during the last quarter. Thurston Springer Miller Herd &amp; Titak Inc. grew its position in shares of CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after buying an additional 382 shares during the last quarter. Finally, Optiver Holding B.V. grew its position in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after buying an additional 210 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该公司的持股。Mcguire Capital Advisors Inc.在第四季度购买了 CRISPR Therapeutics 的新头寸，价值 25,000 美元。Ramirez Asset Management Inc.在第四季度购买了 CRISPR Therapeutics 的新头寸，价值 26,000 美元。Rothschild Investment LLC 在第四季度将其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 现在拥有 562 股该公司股票，价值 29,000 美元，此前在上个季度又购买了 502 股。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度将其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc.现在拥有 576 股该公司股票，价值 30,000 美元，此前在上个季度又购买了 382 股。最后，Optiver Holding B.V.在第三季度将其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V.现在拥有 504 股该公司股票，价值 33,000 美元，此前在上个季度又购买了 210 股。69.20% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>关于 CRISPR Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术修改人类细胞中的基因，旨在为一系列严重疾病创造持久的治疗方案。其研发工作集中在体外和体内应用，能够针对性地修正或破坏致病基因。</p>
</div><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p>
<div class="lb-trans"><p>其主要项目之一是 CTX001，这是一种体外编辑的细胞疗法，旨在治疗镰状细胞病和依赖输血的β-地中海贫血，与 Vertex Pharmaceuticals 合作。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>Before the Moon Base Gets Built, These 4 Companies Win</li>
<li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li>
<li>3 Stocks That Win If Inflation Surprises to the Downside</li>
<li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外向下，三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts

Market Beat

Wisdomtree BioRevolution Fund ETF

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

基因免疫&健康关怀 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

Toronto Dominion Bank

花旗

Piper Sandler Cos

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）被分析师平均推荐为 “适度买入”